FK-506 Inhibitors
FK-506 inhibitors belong to a class of chemical compounds designed to target and modulate the activity of FK-506-binding proteins (FKBPs). FK-506, also known as tacrolimus, is a naturally occurring macrolide produced by the bacterium Streptomyces tsukubaensis. FKBPs are a group of cellular proteins that interact with FK-506, forming a complex that exerts various biological effects, particularly on the immune system. Inhibitors of FK-506 are developed to interact with FKBPs, disrupting the formation of the FK-506-FKBP complex and interfering with the downstream signaling pathways that regulate immune responses and other cellular processes.
FK-506 inhibitors are typically small molecules or compounds designed to bind to FKBPs. By doing so, these inhibitors may alter the immunosuppressive and other cellular effects associated with FK-506. Research into FK-506 inhibitors can provide valuable insights into the molecular mechanisms underlying immunosuppression and immune modulation, offering a deeper understanding of the role of FKBPs in cellular signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
A known inhibitor of CYP3A4; could increase plasma levels of Tacrolimus by reducing its metabolism. | ||||||
Erythromycin | 114-07-8 | sc-204742 sc-204742A sc-204742B sc-204742C | 5 g 25 g 100 g 1 kg | $57.00 $245.00 $831.00 $1331.00 | 4 | |
This compound is a moderate inhibitor of CYP3A4 and may enhance Tacrolimus concentrations by decreasing its clearance. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Diltiazem can inhibit CYP3A4 and potentially increase systemic exposure to Tacrolimus. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
As a CYP3A4 inhibitor, it can raise Tacrolimus blood levels by reducing its metabolic breakdown. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
It moderately inhibits CYP3A4 and can affect Tacrolimus metabolism when co-administered. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
By inhibiting CYP3A4, it could increase the bioavailability of Tacrolimus, reducing its metabolic degradation. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Known to inhibit several CYP enzymes, it may interact with Tacrolimus metabolism, leading to increased levels. | ||||||
Amiodarone | 1951-25-3 | sc-480089 | 5 g | $318.00 | ||
It has been shown to inhibit CYP3A4 activity and could increase Tacrolimus blood concentrations. | ||||||
Nicardipine hydrochloride | 54527-84-3 | sc-202731 sc-202731A | 1 g 5 g | $33.00 $83.00 | 5 | |
Can inhibit CYP3A4-mediated metabolism, potentially increasing Tacrolimus levels. | ||||||
Deoxyschizandrin | 61281-38-7 | sc-278925 | 10 mg | $80.00 | ||
A component of Schisandra chinensis fruit that can inhibit CYP3A4 and might affect Tacrolimus metabolism. | ||||||